FLT3 and plasma cell myeloma: miR-15a/16-1 are also deregulated in over 50% of myeloma patients [77], and patient studies showed significant downregulation of miR-15a/16-1 in CD135+ myeloma cells in comparison to normal counterparts [80, 81].